RESEARCH PLATFORM
FOR DRUG DEVELOPMENT

FIRST-IN-HUMAN DATA GENERATION

Our platform uses real ex vivo donor-derived adipose tissue models to mimic pathological conditions related to obesity and chronic metabolic diseases and generate first-in-human data to increase clinical success of novel drug candidates and pharmacological approaches.
Learn More

For a paradigm shift in obesity research

Obesity is associated with chronic metabolic diseases, such as MASH, liver steatosis, type-2 diabetes and cardiovascular diseases. Despite the emergence of novel effective treatments in recent years, millions of people with obesity remain with no tailored therapeutic solution, in particular patients who are poorly responding to anti-obesity drugs.

Obesity is accompanied by low-grade, chronic inflammation and fibrosis of fat tissue, in particular visceral fat, which contributes to insulin resistance. In addition, the balance between white fat (the ‘bad’ fat) and brown fat (the ‘good’ fat) is altered, with white fat accumulating and becoming dysfunctional, while brown fat and its energy expenditure capabilities are impaired.

Reproducing a pathological and clinically relevant fibro-inflammatory state of adipose tissue ex vivo is essential for developing next-generation drug candidates that target and treat the root causes of obesity and elicit beneficial responses such as energy expenditure.

A Breakthrough Technology for Chronic Metabolic Disorders and Obesity

Our technology overcomes the barrier of ex vivo culture of a viable and metabolically active adipose tissue closely mimicking clinical context

Our technology allows us to mimic ex vivo physio-pathological conditions of human adipose tissue associated to obesity and chronic metabolic diseases for a fine understanding of mechanisms of actions of lead drug candidates for these indications.

Our adipose tissue models are directly derived from donors with different profiles (obesity, chronic metabolic diseases, etc) and are designed to closely reproduce clinical conditions in the lab, thus being a powerful tool to generate first-in-human ex vivo data in clinically relevant target patient populations to accelerate and reduce attrition rate of drug development targeting energy expenditure and chronic fibro-inflammation associated to metabolic diseases and obesity.

ObAdEx has received Deeptech label by BpiFrance and is being developed in collaboration with SATT Sud-Est, CNRS, Nice University Hospital and Côte d’Azur University/Idex.

2023

Early
development

2024

Process scale-up
& industrial adaptation

2025

Non-regulatory
preclinical

2026

Clinical batch &
Bridging studies

2027

First-in-patient
ENERGY EXPENDITURE,
BEIGING OF ADIPOSE TISSUE
ExAdEx models offer the unique capability to study the induction of brown fat-like characteristics (browning/beiging) and energy expenditure in ex vivo human adipose tissue derived from target patient populations. This provides a clinically relevant platform for developing therapies targeting metabolic health and obesity
Browning & Energy Expenditure
PATIENT SEGMENTATION,
PREDICTIVE ANALYSIS
ExAdEx donor-derived tissue models can simulate a variety of patient profiles and disease states ex vivo, effectively recreating a panel of clinical trial scenarios in the lab and enabling more accurate, data-driven prediction of clinical outcomes in target patients subpopulations compared to traditional animal models
Cohort identification
CHRONIC FIBROSIS AND
INFLAMMATION
ExAdEx donor-derived tissue models mimic the chronic fibrosis and inflammation found in human visceral fat, helping to advance more effective treatements for obesity-related metabolic diseases in a clinically relevant context ex vivo
Fibro-inflammation
ExAdEx physio-pathological 3D vascularized and functional models are a relevant alternative to animal testing and provide an original approach for the repositioning of dermo-cosmetics, nutraceutical products and aesthetic regenerative medicine products through evaluation of multiple claims at once, all in single multi-parametric studies.
ExAdEx 3D tissue models are directly derived from human donor subcutaneous adipose tissue, allowing for first-in-human data generation. Thanks to the ExAdEx patented breakthrough technology, our 3D models are alive for up to 8 weeks in tailored unique culture conditions, can reproduce inflammatory and fibrotic stress and preserve the donor's extracellular matrix, vascular and lymphatic networks.
Our cutting-edge ExAdEx platform offers unparalleled insights into tissue-level effects using state-of-the-art 3D imaging and analysis techniques, combining innovative technologies to mimic in vivo conditions and uncover critical biological data. ExAdEx technological platform has a strong and deep connection with French academic research of excellence (CNRS, INSERM, Université Côte d’Azur/IdEx) with decades of expertise in generation of relevant tissue models.
Check our catalog here

GET IN TOUCH

We are happy to answer all your questions, discuss your needs and provide you with tailored solutions.
Please contact us and we will answer as soon as possible.
EXADEX-INNOV
Bioincubateur
Institut de Biologie Valrose
28 Avenue de Valombrose
06100 Nice (FRANCE)

Legal mentions

Copyright © 2022 ExAdEx-Innov All rights reserved

KOL on adipose tissue biology.

Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice). 

Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program). 

Co-inventor of 5 patents

Expert in clinical applications of adipose tissue.

Plastic Reconstructive and Aesthetic Surgeon in Nice.

Member of the Medical Council of Alpes Maritimes region.

Expert for the French National Regulatory Agency ANSM for medical devices.

Certified by French Health Autority HAS (2020-2024).

PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.

Expert in cell therapy and immunology. 

Senior Lecturer (Maitre de conférences).

Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).

Director of « Micoralis » research team at Université Côte d’Azur (Nice).

Founder and CEO of the biotech company Biointerférence (2003-2006).

Co-inventor of 5 patents.

Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.

With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov. 

In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille). 

He is co-inventor of the 2 company’s patent families. 

Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue. 

Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.

With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years. 

He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.

Main areas of expertise: Biotech Startup Business Development; Project management